GLP-1 Cost Guide: Insurance, Savings Programs, and Compounding Options

GLP-1 medications like Ozempic, Mounjaro, and Wegovy are among the most effective tools available for weight loss and metabolic health. They are also among the most expensive. Without insurance, a single month of treatment runs $900 to $1,500 depending on the drug and dose. That is $10,800 to $18,000 per year.

But the list price is not always the price you pay. Between manufacturer savings cards, insurance negotiations, compounding pharmacies, and telehealth platforms, most people can find a path to affordable treatment. This guide breaks down every option so you can make an informed decision with your provider and your wallet.

The Real Cost of GLP-1 Medications

The wholesale acquisition cost (WAC) -- what pharmacies pay before markups -- sets the floor. Retail pharmacy prices add a margin on top of that. Here is what each brand-name GLP-1 medication costs at a typical US retail pharmacy without any insurance or discount, as of early 2026:

A few things to note about these numbers. Ozempic and Wegovy contain the same molecule (semaglutide) but Wegovy costs more because the maintenance dose is higher (2.4 mg vs. up to 2 mg) and it carries a dedicated weight-management indication. Mounjaro and Zepbound are both tirzepatide from Eli Lilly -- Mounjaro is approved for type 2 diabetes, while Zepbound is the weight-management version. Pricing is nearly identical.

These prices reflect the cash-pay sticker price. Very few people actually pay this amount. The real question is which cost-reduction pathway works for your situation. That depends on your insurance status, your diagnosis, and where you live.

Insurance Coverage: What’s Covered and What’s Not

Insurance coverage for GLP-1 medications is one of the most confusing areas in healthcare right now. Whether you are covered depends on three factors: your diagnosis, your plan type, and your insurer’s formulary. Here is how it breaks down by plan type.

Commercial Insurance (Employer-Sponsored and ACA Plans)

Most commercial plans cover Ozempic and Mounjaro when prescribed for type 2 diabetes. Coverage for weight management is a different story. As of early 2026, roughly 40-50% of large employer plans cover anti-obesity medications like Wegovy or Zepbound, up from about 25% in 2023. The trend is toward more coverage, but it is far from universal.

• With a T2D diagnosis: Ozempic and Mounjaro are typically Tier 2 or Tier 3 formulary drugs. Copays range from $25 to $150/month after deductible.
• For weight management only: Wegovy and Zepbound coverage varies dramatically. Some plans cover them with prior authorization; others exclude anti-obesity medications entirely.
• Prior authorization: Nearly universal. Expect to document a BMI of 30+ (or 27+ with a comorbidity like hypertension, sleep apnea, or PCOS), plus evidence that diet and exercise alone were insufficient.

Medicare Part D

Historically, Medicare Part D has not covered anti-obesity medications. Ozempic and Mounjaro are covered for enrollees with a type 2 diabetes diagnosis. The Inflation Reduction Act of 2022 capped insulin costs and improved Part D benefits, but did not extend coverage to weight-loss drugs specifically. Some Medicare Advantage plans have begun adding supplemental coverage for Wegovy, but this is plan-specific and not guaranteed. If you are on Medicare and want a GLP-1 for weight loss, check your plan’s formulary or call the plan directly.

Medicaid

Medicaid coverage varies by state. Most state Medicaid programs cover Ozempic for type 2 diabetes. Coverage for Wegovy or Zepbound for weight management is rare but expanding. States like New York and California have been among the first to add anti-obesity medication coverage. Check your state Medicaid formulary or contact your managed care organization.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly run savings card programs that can dramatically reduce your out-of-pocket costs. These programs are the single biggest cost reducer for commercially insured patients.

Novo Nordisk Savings Cards (Ozempic and Wegovy)

Novo Nordisk offers savings cards through its NovoCare program. The details shift periodically, but as of early 2026:

• Ozempic Savings Card: Eligible patients with commercial insurance may pay as little as $25 per 1-month or 3-month prescription fill. Maximum savings of $150 per fill, up to 24 months.
• Wegovy Savings Card: Similar structure. Commercially insured patients can pay as little as $0 per month for the first 3 months, then reduced copays thereafter. Cash-pay patients are typically not eligible for the full discount.
• Patient Assistance Program (PAP): Uninsured patients with household income below 400% of the federal poverty level may qualify for free medication through NovoCare.

Eli Lilly Savings Cards (Mounjaro and Zepbound)

Lilly’s savings program has been notably aggressive in competing for market share:

• Mounjaro Savings Card: Eligible commercially insured patients may pay as little as $25 per monthly prescription. Not valid for government-insured patients (Medicare, Medicaid, Tricare).
• Zepbound Savings Card: Similar to Mounjaro. Lilly has periodically offered direct-to-consumer pricing of $399/month for cash-pay patients through LillyDirect, bypassing insurance entirely.
• Lilly Cares Foundation: Patient assistance for uninsured or underinsured patients. Income-based eligibility.

Compounding Pharmacies: A Lower-Cost Alternative

Compounding pharmacies have emerged as a significant cost-reduction option, especially for patients without insurance coverage. Compounded semaglutide and tirzepatide typically cost $100 to $400 per month -- a fraction of brand-name pricing. But this option comes with important nuances around legality, safety, and quality.

What Compounded GLP-1s Are

A compounding pharmacy creates customized medications from raw pharmaceutical ingredients. For GLP-1s, this means purchasing semaglutide or tirzepatide active pharmaceutical ingredient (API) and formulating it into injectable solutions. These are not generic medications -- they are pharmacy-prepared versions that have not gone through the FDA approval process for safety and efficacy.

The Legal Landscape

Under the Federal Food, Drug, and Cosmetic Act (section 503A and 503B), compounding pharmacies can produce copies of FDA-approved drugs when those drugs are on the FDA’s official drug shortage list. Semaglutide was listed as in shortage from 2022 through early 2024. Tirzepatide was listed from late 2022 through 2024. As shortages resolve, the FDA has moved to restrict compounding of these drugs. The legal status is actively evolving, with court challenges from compounding pharmacy trade groups and shifting FDA guidance.

How to Evaluate a Compounding Pharmacy

If you choose the compounding route, quality matters enormously. Not all compounding pharmacies are equal. Here is what to look for:

• 503B outsourcing facility: These are FDA-registered and subject to cGMP (current Good Manufacturing Practice) inspections. They are held to a higher standard than 503A pharmacies.
• Third-party testing: Ask if the pharmacy performs independent potency and sterility testing on each batch. Reputable pharmacies will provide certificates of analysis (COAs).
• State licensing: Verify the pharmacy is licensed in your state. Compounding regulations vary significantly by state.
• Prescription requirement: Any legitimate compounding pharmacy requires a valid prescription from a licensed provider. If a pharmacy offers GLP-1s without a prescription, walk away.

Telehealth Platforms and Online Prescribers

Telehealth has made GLP-1 access significantly easier. Instead of finding a local provider willing to prescribe, scheduling an in-person visit, and navigating insurance referrals, you can often get evaluated, prescribed, and supplied through a single online platform. Here is how the landscape looks as of early 2026.

What Telehealth Platforms Typically Include

• Medical evaluation: An asynchronous or video consultation with a licensed provider who reviews your health history, BMI, labs, and goals.
• Lab work: Some platforms order metabolic panels and A1c testing. Others accept recent labs from your PCP.
• Prescription management: Monthly or quarterly check-ins, dose adjustments, and refill management.
• Medication fulfillment: Some platforms partner with retail pharmacies (you pick up your brand-name medication locally). Others use affiliated compounding pharmacies and ship directly.
• Support: Nutritional coaching, messaging with providers, and community access vary by platform and price tier.

Pricing Structures

Telehealth GLP-1 pricing typically falls into two buckets:

The all-inclusive compounded model has become popular because of its simplicity: one monthly fee, medication shows up at your door, and provider check-ins are included. However, you are subject to all the compounding risks and regulatory uncertainties discussed above. The brand-name model keeps your medication at FDA-approved quality but adds the complexity (and potential savings) of insurance navigation.

How to Reduce Your GLP-1 Costs

Regardless of your insurance situation, there are practical strategies that can meaningfully reduce what you pay. Here are the most effective approaches, roughly ordered by impact.

1. Use Manufacturer Savings Cards First

If you have commercial insurance, this is the single highest-impact move. A savings card from Novo Nordisk or Eli Lilly can bring your copay down to $25/month. Apply before your first fill. These stack on top of your insurance benefits and are free to enroll.

2. Compare Pharmacy Prices

GLP-1 prices vary by 15-30% between pharmacies in the same city. Use GoodRx, RxSaver, or Optum Perks to compare. Costco (no membership required for pharmacy), mail-order pharmacies like Amazon Pharmacy or Alto, and independent pharmacies often beat CVS and Walgreens on cash price.

3. Ask About Step Therapy and Formulary Alternatives

If your insurance denies Wegovy but covers Ozempic, your doctor may be able to prescribe Ozempic off-label for weight loss at a dose close to Wegovy’s. Similarly, if Zepbound is not covered but Mounjaro is, a T2D diagnosis or comorbidity documentation might get Mounjaro approved. Work with your prescriber on the strategy -- they deal with insurance obstacles daily.

4. Optimize Your Dosing Timeline

Slow titration is not just safer -- it can save money. If you tolerate 5 mg of Mounjaro well and are losing weight steadily, there is no clinical requirement to rush to 10 or 15 mg. Lower doses mean lower costs, especially if you are paying out of pocket. Discuss dose optimization with your provider.

5. Explore Patient Assistance Programs

If you are uninsured or underinsured, both Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares) offer free medication to qualifying patients. Income thresholds are typically 400% of the federal poverty level -- roughly $62,000/year for an individual or $128,000 for a family of four in 2026. Application takes 2-4 weeks.

6. Consider Mail-Order and 90-Day Fills

Many insurance plans offer lower per-unit costs for 90-day mail-order prescriptions versus 30-day retail fills. If your plan has this option, switching to 90-day fills can save 10-20% over the year. Ask your insurance company or check your plan’s preferred mail-order pharmacy.

Frequently Asked Questions

How much does Ozempic cost without insurance?

Without insurance, Ozempic runs approximately $900 to $1,100 per month at most US retail pharmacies as of early 2026. The exact price depends on the pen dose (0.25 mg to 2 mg), your pharmacy, and your region. Using GoodRx or a similar discount tool can sometimes shave $50-$150 off the cash price. Novo Nordisk’s savings card is only available to commercially insured patients, not cash-pay. Uninsured patients earning below 400% of the federal poverty level may qualify for free medication through NovoCare’s patient assistance program.

Does insurance cover Wegovy for weight loss?

It depends on your plan. As of early 2026, roughly 40-50% of large employer-sponsored commercial plans cover Wegovy for weight management, typically with prior authorization. Medicare Part D generally does not cover anti-obesity medications, though some Medicare Advantage plans have added supplemental coverage. Medicaid coverage varies by state. If your plan does not cover Wegovy specifically, ask your prescriber whether Ozempic (same molecule, lower dose, broader coverage) could work for your situation.

What are compounded GLP-1 medications, and are they safe?

Compounded GLP-1s are versions of semaglutide or tirzepatide prepared by licensed compounding pharmacies from raw pharmaceutical ingredients. They cost $100 to $400/month, making them the cheapest option. However, they are not FDA-approved, which means no standardized quality assurance from the manufacturer. Safety depends heavily on the pharmacy. Look for 503B outsourcing facilities that provide third-party potency and sterility testing. The legal availability of compounded GLP-1s depends on whether the branded versions are on the FDA’s drug shortage list -- a status that changes and has been the subject of ongoing legal challenges.

How can I save money on Mounjaro?

Start with Eli Lilly’s Mounjaro Savings Card -- commercially insured patients may pay as low as $25 per fill. Compare pharmacy prices using GoodRx (prices vary by 15-30% between pharmacies). If your insurance does not cover Mounjaro for weight loss, ask your doctor about documenting a type 2 diabetes or prediabetes diagnosis if clinically appropriate. Consider LillyDirect at $399/month for Zepbound if you are paying cash. Finally, do not rush dose titration -- staying at an effective lower dose saves money if you are paying out of pocket.

Are telehealth GLP-1 prescriptions legitimate?

Yes, when issued by licensed providers through established platforms. Legitimate telehealth services employ board-certified physicians or nurse practitioners who review your medical history, order or review lab work, and write prescriptions filled at licensed pharmacies. Red flags to watch for: platforms that prescribe without any medical evaluation, do not ask about your health history or current medications, do not require lab work, or ship medications from unverified overseas sources. A legitimate prescriber will also have a plan for managing side effects and will be reachable if you have complications.

Key Takeaways

• Brand-name GLP-1 medications cost $900-$1,500/month without insurance. Ozempic and Mounjaro are at the lower end; Wegovy is at the higher end due to its higher dose.
• Manufacturer savings cards are the biggest cost reducer for commercially insured patients. Both Novo Nordisk and Eli Lilly offer programs that can drop copays to $25/month.
• Insurance coverage depends on diagnosis and plan type. Type 2 diabetes coverage is broad. Weight-management-only coverage is expanding but inconsistent across plans and payers.
• Compounded GLP-1s cost $100-$400/month but carry quality and regulatory risks. If you go this route, choose a 503B facility with third-party testing and verify current FDA shortage status.
• Telehealth platforms simplify access but vary in quality and medication sourcing. Ask where the medication comes from and whether the prescriber is licensed in your state.
• Practical cost-saving strategies stack. Savings cards + pharmacy shopping + dose optimization + mail-order fills can reduce annual costs by thousands of dollars.
• Consult your healthcare provider and insurance company. Prices and coverage change frequently. Your provider’s office deals with insurance navigation daily and can often help with prior authorizations and appeals.

For a detailed comparison of how these medications differ in mechanism, dosing, and clinical outcomes, read our Ozempic vs Mounjaro vs Wegovy guide. For what to expect after starting treatment, see the GLP-1 Week-by-Week Timeline.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Link
3. U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. Revised 2025. Link
4. U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. Revised 2025. Link
5. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. Revised 2024. Link
6. KFF. Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. 2024. Link
7. KFF. Medicaid coverage of and spending on GLP-1s. 2025. Link